Table 2A.

AACR GENIE Lung Adenocarcinoma Co-Occurring Mutations

	All lung adenocarcinomas (n = 5,060 samples)
TP53 mutation*	2,333 (46.1%)
KRAS mutation**	1,649 (32.6%)
STK11 mutation***	665 (13.4%)
Mutations#	All TP53 mutations n = 1,667 samples (1,750 missense mutations)	Lung-enriched TP53 mutations (V157, R158, A159) n = 146 samples (147 missense mutations)
TP53 without KRAS or STK11	1,100 (66.0%)	86 (58.9%)
TP53 and KRAS	434 (26.0%)	52 (35.6%)
TP53 and STK11	185 (11.1%)	12 (8.2%)
TP53, KRAS, and STK11	52 (3.1%)	4 (2.7%)

^*TP53 mutations include 2,325 samples with mutations, 3 samples with fusions, and 5 samples with multiple alterations.

^**KRAS mutations include 1,625 samples with mutations and 24 samples with multiple alterations.

^***STK11 mutations include 652 samples with mutations, 12 samples with fusions, and 1 sample with multiple alterations.

Amplifications and deep deletions are excluded.

^#Frequency is represented in percent of samples with missense mutations out of total number of samples with TP53 missense mutations.